Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O'Shaughnessy,Susana Sousa,Josefina Cruz,Lesley Fallowfield,Päivi Auvinen,Catarina Pulido,Ana Cvetanovic,Sharon Wilks, Leonor Ribeiro,Mauricio Burotto,Dirk Klingbiel,Dimitri Messeri,Ari Alexandrou,Peter Trask,Judy Fredriksson,Zuzana Machackova,Ljiljana Stamatovic

European Journal of Cancer（2021）

引用 17|浏览18

暂无评分

摘要

Image 1

查看译文

关键词

Pertuzumab,Trastuzumab,Early breast cancer,Adjuvant,Subcutaneous,Fixed dose,Patient-reported outcomes,Patient preference,Healthcare resource,Quality of life

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要